The FDA warning last week on the cardiovascular effects of non-aspirin nonsteroidal anti-inflammatory drugs has prompted healthcare experts to advise caution when using these drugs on a regular basis.
The FDA warning last week on the cardiovascular (CV) effects of non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) like Motrin IB, Aleve, and Celebrex, has prompted a debate among healthcare experts: how do we regulate the pill popping phenomenon that has emerged, even for minor aches and pains?
While current labels for both over-the-counter (OTC) and prescription NSAIDs indicate heart risks, the FDA said in its announcement that prescription NSAIDs would need a drug label update to reflect the following:
Although the risk of a heart attack or stroke from NSAID use does not match up with the risks associated with smoking or obesity, it does exist. Peter Wilson, MD, from Emory University in Atlanta who was on the FDA panel last year that evaluated the more recent evidence, said in an interview that while these drugs are widely viewed as benign “they are probably not,” adding that OTC NSAIDs may increase the risk by 10%, low-dose prescription NSAIDs by about 20%, and high-dose prescriptions NSAIDs by about 50%.
However, a lot of variables are yet to be determined, such as safety of one product over another, safe dose or duration of treatment, etc. The lack of additional and more definitive information has prompted experts to recommend that people should weigh the risk-to-benefit with these medications and that the new warnings might encourage pain management without drugs or divert attention to treating the underlying cause of the pain. According to Bruce Lambert, director of the Center for Communication and Health at Northwestern University, “For people who are in the habit of taking these drugs for headaches or mild pain, they might want to reconsider.”
Dr Kathryn Lindley on Pregnancy-Related Cardiovascular Care Gaps and Training Initiatives
December 8th 2023Cardiologists need skills in risk assessment, contraception counseling, and hypertension management for pregnant patients, according to Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More